InterMune News Releases

ABOUT US

PRODUCTS

PIPELINE

CAREERS

2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Replay
Robert W. Baird & Co. Small Cap Healthcare Conference
September 10, 2008, 10:30 AM ET

Replay
Q3 2008 Earnings Conference Call
November 6, 2008, 4:30 PM ET

Replay
2008 DB-BIOTECH BOSTON CONFAB
November 11, 2008, 4:00 PM ET

Replay
Lazard Capital Markets 5th Annual Healthcare Conference
November 18, 2008, 3:10 PM ET

Date	Title (click to view the full text)
Most Recent Releases
11/14/08	InterMune to Present at Lazard Capital Markets Healthcare Conference
11/10/08	Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
11/7/08	InterMune to Present at Deutsche Bank Biotech Boston Confab
11/6/08	InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10/28/08	InterMune to Release Third Quarter 2008 Financial Results on November 6
10/16/08	InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
9/24/08	InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
9/8/08	InterMune to Present at Baird Small Cap Healthcare Conference
9/2/08	InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8/29/08	InterMune to Present at Thomas Weisel Partners Healthcare Conference
8/7/08	InterMune to Present at Canaccord Adams Conference
7/30/08	InterMune to Present at BMO Healthcare Conference
7/24/08	InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6/20/08	InterMune to Present at Jefferies Healthcare Conference
6/6/08	InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
5/29/08	InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
5/19/08	InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
5/16/08	InterMune to Present at Citigroup Healthcare Conference
5/9/08	InterMune to Present at Bank of America Health Care Conference
5/1/08	InterMune Reports First Quarter 2008 Financial Results and Business Highlights
4/30/08	InterMune to Present at Deutsche Bank Health Care Conference
4/24/08	InterMune to Release First Quarter 2008 Financial Results on May 1
4/21/08	InterMune Announces Progress on Pirfenidone in IPF
4/2/08	InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
4/1/08	InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3/18/08	Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
3/12/08	InterMune to Present at Cowen and Company and Lehman Brothers Health Care Conferences
2/28/08	InterMune to Present at the SIGnificant Options in Healthcare Conference
2/7/08	InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
1/24/08	InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7
1/23/08	InterMune to Present at the 2008 Wachovia Healthcare Conference
1/7/08	InterMune Announces Continuing Progress on ITMN-191 (R7227)
1/2/08	InterMune to Present at the 26th Annual JPMorgan Healthcare Conference
11/26/07	InterMune Buys Out License Agreement for Pirfenidone
11/1/07	InterMune Announces Third Quarter 2007 Financial Results and Business Highlights
10/31/07	InterMune to Present at CIBC Healthcare Conference
10/22/07	InterMune to Release Third Quarter 2007 Financial Results on November 1
9/26/07	InterMune Announces Closing of Public Offering of Common Stock
9/26/07	InterMune Announces Start of Phase 1b Trial of ITMN-191
9/21/07	InterMune Announces Pricing of $68 Million Public Offering of Common Stock
2005
Date	Title (click to view the full text)
12/27/05	InterMune Announces Divestiture of Oritavancin
12/1/05	InterMune Elects David S. Kabakoff, Ph.D. To Board Of Directors
11/28/05	InterMune Sharpens Focus on Key Development Programs and Significantly Strengthens Financial Position
11/14/05	InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV
11/14/05	InterMune Presents HCV Protease Inhibitor Data at AASLD
11/9/05	InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
11/8/05	InterMune Announces Presentations at the 56th Annual Meeting of the American Association for the Study of Liver Diseases
11/1/05	InterMune Presents In Vitro Data at Annual Meeting of the American College of Chest Physicians
10/27/05	InterMune Announces Third Quarter Financial Results and Business Highlights
10/20/05	InterMune Announces Presentations at Annual Meeting of the American College of Chest Physicians
10/17/05	InterMune Provides Update on Its Two Phase III Pulmonology Programs
10/14/05	InterMune to Release Third Quarter Financial Results on October 27
9/21/05	InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
9/8/05	InterMune Announces Webcast of Corporate Presentation at the ThinkEquity Partners Growth Conference
9/7/05	Intermune Announces Issuance of Two Composition of Matter Patents for Actimmune(R)
7/28/05	InterMune Announces Second Quarter Financial Results
7/19/05	InterMune and Array BioPharma Expand Hepatitis C Drug Discovery Collaboration
7/12/05	InterMune to Release Second Quarter Financial Results on July 28
7/11/05	InterMune Completes Enrollment of the Phase III DIRECT Trial Evaluating Daily Infergen Plus Ribavirin in PEG-Nonresponders
6/2/05	InterMune Announces Webcast of Corporate Presentation at the Pacific Growth Equities Life Sciences Conference
5/24/05	InterMune Announces Divestiture of Amphotec
5/23/05	Data Presented at ATS 2005 Support Intermune's Current Phase III Trial Design Evaluating Actimmune(R) in IPF Patients
5/16/05	InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
5/16/05	InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders
5/16/05	InterMune Announces Presentation of Specificity and Tolerability Data for Two Novel Protease Inhibitor Drug Candidates
5/9/05	InterMune Reaches Preliminary Settlement Agreement for Shareholder Class Action Lawsuit
5/9/05	InterMune Announces Hepatitis C Presentations at Digestive Disease Week
5/9/05	InterMune Announces Presentations on Actimmune and IPF at ATS 2005
5/2/05	Promising Results From Phase II Study of Pirfenidone in IPF Patients
4/28/05	InterMune Announces First Quarter Financial Results
4/7/05	InterMune to Release First Quarter Financial Results on April 28
3/29/05	InterMune Provides an Update on Pirfenidone Development Plans
3/9/05	InterMune Announces Webcast of Corporate Presentation at the SG Cowen & Co. 25th Annual Health Care Conference
2/23/05	Intermune Announces Webcast of Corporate Presentation at the Wells Fargo 2005 Healthcare Conference
2/23/05	InterMune Announces Webcast of Corporate Presentation at the JMP Securities 4th Annual Research Conference
2/18/05	InterMune Announces Management Appointment
2/7/05	InterMune Announces Fourth Quarter and Year End Financial Results
1/25/05	InterMune to Release Fourth Quarter and Year-End 2004 Financial Results on February 7
1/10/05	InterMune Announces Webcast of Corporate Presentation at the JPMorgan Healthcare Conference
1/10/05	Largest Completed IPF Study Points to Survival as Key Endpoint in Future Actimmune Studies

E-mail Alert Service:

Subscribe to the News Releases Alert service. As a subscriber, you will receive an e-mail alert whenever this type of company information is added to this Web site.

Enter your e-mail address: